These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 20495510

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C.
    Transplant Proc; 2005 Mar; 37(2):1151-2. PubMed ID: 15848653
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
    Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, Bain VG, Wall WJ, Roy A, Balshaw RF, Barkun JS.
    Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
    Sarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O.
    Transplantation; 2003 Nov 15; 76(9):1331-9. PubMed ID: 14627912
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
    Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG.
    Transplantation; 2000 Jan 27; 69(2):307-11. PubMed ID: 10670644
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
    Rostaing L, Cantarovich D, Mourad G, Budde K, Rigotti P, Mariat C, Margreiter R, Capdevilla L, Lang P, Vialtel P, Ortuño-Mirete J, Charpentier B, Legendre C, Sanchez-Plumed J, Oppenheimer F, Kessler M, CARMEN Study Group.
    Transplantation; 2005 Apr 15; 79(7):807-14. PubMed ID: 15818323
    [Abstract] [Full Text] [Related]

  • 17. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids.
    Glotz D, Charpentier B, Abramovicz D, Lang P, Rostaing L, Rifle G, Vanrenterghem Y, Berthoux F, Bourbigot B, Delahousse M, Chalopin JM, Cassuto E, Lefrançois N.
    Transplantation; 2010 Jun 27; 89(12):1511-7. PubMed ID: 20386144
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A.
    Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943
    [Abstract] [Full Text] [Related]

  • 20. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
    González-Roncero FM, Gentil-Govantes MÁ, González-Molina M, Rivero M, Cantarell C, Alarcón A, Franco A, Sánchez-Plumed J, Lampreabe I, Lauzurica R, González E, Romero R, Ruiz-San Millán JC, Osuna A.
    Nefrologia; 2012 Jul 17; 32(4):446-54. PubMed ID: 22806279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.